248 related articles for article (PubMed ID: 36367663)
1. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
Mohamed F; Mansfield BS; Raal FJ
Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
[TBL] [Abstract][Full Text] [Related]
2. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
[TBL] [Abstract][Full Text] [Related]
3. A novel fully human anti-NT-ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL-C lowering activities in hyperlipidemia mice.
Zhang P; Wang K; Hu T; Xu M; You X; Chen M; Tang X; Hu H; Jiang Y; Zhao W; Tan S
FASEB J; 2024 Jan; 38(1):e23399. PubMed ID: 38174870
[TBL] [Abstract][Full Text] [Related]
4. ANGPTL3 as therapeutic target.
Kersten S
Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
Mohamed F; Botha TC; Raal FJ
Curr Opin Lipidol; 2021 Aug; 32(4):213-218. PubMed ID: 33883446
[TBL] [Abstract][Full Text] [Related]
6. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.
White RT; Sankey KH; Nawarskas JJ
Cardiol Rev; 2024 Mar-Apr 01; 32(2):180-185. PubMed ID: 37071085
[TBL] [Abstract][Full Text] [Related]
7. Novel therapies for familial hypercholesterolemia.
Mohamed F; Seedat F; Raal FJ
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance.
Adam RC; Mintah IJ; Alexa-Braun CA; Shihanian LM; Lee JS; Banerjee P; Hamon SC; Kim HI; Cohen JC; Hobbs HH; Van Hout C; Gromada J; Murphy AJ; Yancopoulos GD; Sleeman MW; Gusarova V
J Lipid Res; 2020 Sep; 61(9):1271-1286. PubMed ID: 32646941
[TBL] [Abstract][Full Text] [Related]
9. ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism.
Burks KH; Xie Y; Gildea M; Jung IH; Mukherjee S; Lee P; Pudupakkam U; Wagoner R; Patel V; Santana K; Alisio A; Goldberg IJ; Finck BN; Fisher EA; Davidson NO; Stitziel NO
J Lipid Res; 2024 Feb; 65(2):100500. PubMed ID: 38219820
[TBL] [Abstract][Full Text] [Related]
10. ANGPTL3 (Angiopoietin-Like 3) Preferentially Resides on High-Density Lipoprotein in the Human Circulation, Affecting Its Activity.
Kraaijenhof JM; Tromp TR; Nurmohamed NS; Reeskamp LF; Langenkamp M; Levels JHM; Boekholdt SM; Wareham NJ; Hoekstra M; Stroes ESG; Hovingh GK; Grefhorst A
J Am Heart Assoc; 2023 Nov; 12(21):e030476. PubMed ID: 37889183
[TBL] [Abstract][Full Text] [Related]
11. Evinacumab: Mechanism of action, clinical, and translational science.
Dingman R; Bihorel S; Gusarova V; Mendell J; Pordy R
Clin Transl Sci; 2024 Jun; 17(6):e13836. PubMed ID: 38845393
[TBL] [Abstract][Full Text] [Related]
12. Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
Burks KH; Basu D; Goldberg IJ; Stitziel NO
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101688. PubMed ID: 35999139
[TBL] [Abstract][Full Text] [Related]
13. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.
Luo F; Das A; Khetarpal SA; Fang Z; Zelniker TA; Rosenson RS; Qamar A
Trends Cardiovasc Med; 2024 May; 34(4):215-222. PubMed ID: 36746257
[TBL] [Abstract][Full Text] [Related]
14. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan DC; Watts GF
Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
[TBL] [Abstract][Full Text] [Related]
15. New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.
Gaine SP; Quispe R; Patel J; Michos ED
Curr Cardiovasc Risk Rep; 2022 Sep; 16(9):69-78. PubMed ID: 36213094
[TBL] [Abstract][Full Text] [Related]
16. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
Gobeil É; Bourgault J; Mitchell PL; Houessou U; Gagnon E; Girard A; Paulin A; Manikpurage HD; Côté V; Couture C; Marceau S; Bossé Y; Thériault S; Mathieu P; Vohl MC; Tchernof A; Arsenault BJ
Eur Heart J; 2024 Mar; 45(9):707-721. PubMed ID: 38243829
[TBL] [Abstract][Full Text] [Related]
17. Effects of exercise training on ANGPTL3/8 and ANGPTL4/8 and their associations with cardiometabolic traits.
Hoffmann WG; Chen YQ; Schwartz CS; Barber JL; Dev PK; Reasons RJ; Miranda Maravi JS; Armstrong B; Gerszten RE; Silbernagel G; Konrad RJ; Bouchard C; Sarzynski MA
J Lipid Res; 2024 Feb; 65(2):100495. PubMed ID: 38160757
[TBL] [Abstract][Full Text] [Related]
18. Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease.
Heo JH; Jo SH
J Korean Med Sci; 2023 Sep; 38(38):e295. PubMed ID: 37750369
[TBL] [Abstract][Full Text] [Related]
19. Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets.
Chen J; Fang Z; Luo Q; Wang X; Warda M; Das A; Oldoni F; Luo F
Lipids Health Dis; 2024 Jan; 23(1):14. PubMed ID: 38216994
[TBL] [Abstract][Full Text] [Related]
20. New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing.
Srivastava RAK
Nutr Metab Cardiovasc Dis; 2023 Dec; 33(12):2317-2325. PubMed ID: 37805309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
